It is distinct from Rybelsus, which is lower-dose oral semaglutide for type 2 diabetes, and, following MHRA approval in June 2026, is rolling out on private prescription during the second half of 2026 rather than on the NHS
Overall prescribing trends The study found that 2,185,238 patients were prescribed a GLP-1 RA between January 2019 and December 2025, with 11,194,909 total prescriptions during this period
Insulin Dose Reduction at GLP-1 RA Initiation In the SUSTAIN-5 trial (N=397), patients on semaglutide 1 mg plus basal insulin experienced a symptomatic hypoglycemia rate of 11.3%, versus 1.1% in the semaglutide-plus-metformin-only arm [6]
Participants receiving the 2.4 mg weekly dose experienced average weight loss of 14-18% of their body weight over 68 weeks, compared to 2-3% with placebo
Efficacy and Safety of Ashwagandha (Withania somnifera (L.) Dunal) Root Extract in Improving Memory and Cognitive Functions [online]